X4 Pharmaceuticals Inc expected to post a loss of 22 cents a share - Earnings Preview

X4 Pharmaceuticals

02/05/2023 19:37

* X4 Pharmaceuticals Inc  XFOR.OQ   XFOR.O  is expected
to show no
change in quarterly revenue when it reports  results on May 4. 
    * 
    * ​Refinitiv's mean analyst estimate for X4 Pharmaceuticals
Inc is
for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.0%
in the last three months. ​
    * Wall Street's median 12-month price target for X4
Pharmaceuticals Inc is $3​, above​ its last closing price
of $1.57. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.31       -0.24      -0.29     Missed  -20.2
 Sep. 30 2022  -0.65       -0.30      -0.26     Beat    13.1
 Jun. 30 2022  -0.60       -0.64      -0.60     Beat    6​
 Mar. 31 2022              -0.61      -0.72     Missed  -18.3
 ​​Dec.        -0.74       -0.68      -0.90     Missed  -31.8
 31 2021                                                
 Sep. 30 2021  -0.74       -0.72      -0.76     Missed  -5.2​
 Jun. 30 2021  -0.89       -0.74      -0.74     Met     -0.2
 Mar. 31 2021  -0.94       -0.86      -1.30     Missed  -51.4
 This summary was machine generated May 2 at 18:37 GMT.  All
figures in US dollars  unless otherwise stated